肺癌治疗疗效的更新网络荟萃分析：一项系统评价与荟萃分析

The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis.

作者信息

Chang Chuan-Hsin, Chien Chih-Cheng, Chang Yue-Cune

机构信息

Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.

Research Center for Chinese Herbal Medicine, Graduate Institute of Healthy Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan.

出版信息

Tzu Chi Med J. 2025 Jun 30;37(3):339-347. doi: 10.4103/tcmj.tcmj_264_24. eCollection 2025 Jul-Sep.

DOI:10.4103/tcmj.tcmj_264_24

PMID:40741618

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12306890/

Abstract

OBJECTIVES

Lung cancer is one of the most common malignancies worldwide. We aim to investigate the most effective treatments for advanced/nonadvanced stages of lung cancer patients.

MATERIALS AND METHODS

We searched electronic databases to investigate the treatment efficacies of lung cancer. The network meta-analysis was used to identify the top five most effective therapeutic strategies. A total of 157 studies were collected with a cumulative total of 164,678 participants.

RESULTS

The results showed that the best top five treatments: (1) for advanced lung cancer in response rate, were Chemo + Chemotherapy + Targeted Therapy, Cell therapy + Immunotherapy, Targeted Therapy + Radiotherapy, Chemoradiotherapy + Immunotherapy, and Chemotherapy + Chemoradiotherapy with cumulative probabilities 50.5, 49.6, 47.7, 46.0, and 45.6%; (2) for advanced lung cancer in progression-free survival (PFS) rate, were Targeted + Radiotherapy, Targeted + Others Therapy, Targeted + Targeted Therapy, Immu + Immu + Chemo Therapy, and Chemoradiotherapy with cumulative probabilities 99.5, 82.8, 44.9, 36.5, and 33.6%; (3) for nonadvanced lung cancer in response rate, were Chemoradiotherapy + Immu, Chemoradiotherapy + Targeted therapy, Chemoradiotherapy + Others, Chemotherapy + Surgery, and Radiotherapy + Others with cumulative probabilities 79.1, 74.9, 66.9, 60.4, and 54.2%; (4) for non-advanced lung cancer in PFS rate, were Chemo + Surgery, Chemoradiotherapy + Targeted, Surgery, Surgery + Radiotherapy, and Chemoradiotherapy + Others with cumulative probabilities 88.3, 86.1, 78.3, 73.1, and 50.8%.

CONCLUSION

We present the latest and most effective therapeutic strategies for patients with advanced or nonadvanced stages of lung cancer.

摘要

目的

肺癌是全球最常见的恶性肿瘤之一。我们旨在研究针对肺癌患者晚期/非晚期阶段最有效的治疗方法。

材料与方法

我们检索电子数据库以研究肺癌的治疗效果。采用网络荟萃分析来确定最有效的五种治疗策略。共收集了157项研究，累计共有164,678名参与者。

结果

结果显示，最佳的五种治疗方法：（1）对于晚期肺癌的缓解率，依次是化疗+化疗+靶向治疗、细胞治疗+免疫治疗、靶向治疗+放疗、放化疗+免疫治疗、化疗+放化疗，累积概率分别为50.5%、49.6%、47.7%、46.0%和45.6%；（2）对于晚期肺癌的无进展生存期（PFS）率，依次是靶向+放疗、靶向+其他治疗、靶向+靶向治疗、免疫+免疫+化疗、放化疗，累积概率分别为99.5%、82.8%、44.9%、36.5%和33.6%；（3）对于非晚期肺癌的缓解率，依次是放化疗+免疫、放化疗+靶向治疗、放化疗+其他、化疗+手术、放疗+其他，累积概率分别为79.1%、74.9%、66.9%、60.4%和54.2%；（4）对于非晚期肺癌的PFS率，依次是化疗+手术、放化疗+靶向、手术、手术+放疗、放化疗+其他，累积概率分别为88.3%、86.1%、78.3%、73.1%和50.8%。